LYELL IMMUNOPHARMA, INC.

(LYEL)
  Report
Real-time Estimate Cboe BZX  -  05/24 03:27:45 pm EDT
4.140 USD   -3.27%
11:31aGoldman Sachs Adjusts Price Target for Lyell Immunopharma to $12 From $21, Keeps Buy Rating
MT
05/10LYELL IMMUNOPHARMA : Q1 Earnings Snapshot
AQ
05/10LYELL IMMUNOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/18/2022 05/19/2022 05/20/2022 05/23/2022 05/24/2022 Date
3.68(c) 3.88(c) 4.11(c) 4.28(c) 4.18 Last
858 911 803 196 920 277 1 369 128 731 682 Volume
-8.68% +5.43% +5.93% +4.14% -2.34% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 28,4 M - -
Net income 2022 -264 M - -
Net cash position 2022 105 M - -
P/E ratio 2022 -3,95x
Yield 2022 -
Sales 2023 32,7 M - -
Net income 2023 -404 M - -
Net cash position 2023 49,5 M - -
P/E ratio 2023 -2,66x
Yield 2023 -
Capitalization 1 053 M 1 053 M -
EV / Sales 2022 33,4x
EV / Sales 2023 30,7x
Nbr of Employees 219
Free-Float 69,7%
More Financials
Company
Lyell Immunopharma, Inc. is a T-cell reprogramming company. The Company offers T cells to cure patients with solid tumors. Its technologies are designed to be applied in a target and agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies to improve the properties of T cells to eradicate solid tumors. It builds a multi-modality product pipeline... 
More about the company
Ratings of Lyell Immunopharma, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about LYELL IMMUNOPHARMA, INC.
11:31aGoldman Sachs Adjusts Price Target for Lyell Immunopharma to $12 From $21, Keeps Buy Ra..
MT
05/10LYELL IMMUNOPHARMA : Q1 Earnings Snapshot
AQ
05/10LYELL IMMUNOPHARMA, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
05/10Earnings Flash (LYEL) LYELL IMMUNOPHARMA Posts Q1 Revenue $553,000
MT
05/10Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights
GL
05/10Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights
GL
05/10Lyell Immunopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
05/04Lyell Immunopharma to Participate in BofA Securities Healthcare Conference
GL
05/02Lyell Immunopharma to Present Preclinical Data for Two Product Candidates in Clinical D..
GL
05/02Lyell Immunopharma to Present Preclinical Data for Two Product Candidates in Clinical D..
AQ
05/02Lyell Immunopharma to Present Preclinical Data for Two Product Candidates in Clinical D..
CI
03/31JPMorgan Lowers Price Target for Lyell Immunopharma to $15 From $22, Maintains Overweig..
MT
03/31Goldman Sachs Adjusts Lyell Immunopharma Price Target to $21 From $31, Maintains Buy Ra..
MT
03/30SECTOR UPDATE : Health Care Stocks Lean Lower Pre-Bell Wednesday
MT
03/30Lyell Immunopharma Q4 Adjusted Loss Widens as Revenue Rises
MT
More news
News in other languages on LYELL IMMUNOPHARMA, INC.
05/10Earnings Flash (LYEL) LYELL IMMUNOPHARMA affiche un chiffre d'affaires de 553 000 $ pou..
05/10Lyell Immunopharma, Inc. annonce ses résultats pour le premier trimestre clos le 31 mar..
05/02Lyell Immunopharma présentera des données précliniques pour deux produits candidats en ..
03/30MISE À JOUR SECTORIELLE : Les actions du secteur de la santé sont en baisse avant la cloch..
03/30La perte ajustée du 4e trimestre de Lyell Immunopharma se creuse alors que les revenus ..
More news
Analyst Recommendations on LYELL IMMUNOPHARMA, INC.
More recommendations
Chart LYELL IMMUNOPHARMA, INC.
Duration : Period :
Lyell Immunopharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LYELL IMMUNOPHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 4,28 $
Average target price 14,50 $
Spread / Average Target 239%
EPS Revisions
Managers and Directors
Elizabeth Homans Chief Executive Officer & Director
Charles Newton Chief Financial Officer
Richard D. Klausner Chairman
Tina Albertson Chief Medical Officer & Head-Development
Richard D. Goold Chief Information Officer
Sector and Competitors
1st jan.Capi. (M$)
LYELL IMMUNOPHARMA, INC.-44.70%1 053
GILEAD SCIENCES, INC.-12.33%79 850
REGENERON PHARMACEUTICALS, INC.7.98%73 473
VERTEX PHARMACEUTICALS22.20%68 632
WUXI APPTEC CO., LTD.-17.77%42 378
BIONTECH SE-36.69%39 666